Ruxolitinib in CMML: A case study of innovative trial design in a rare cancer

Aditi Shastri; Diego A. Adrianzen-Herrera

doi:10.1158/1078-0432.CCR-21-2578

Ruxolitinib in CMML: A case study of innovative trial design in a rare cancer

Aditi Shastri, Diego A. Adrianzen-Herrera

Oncology

Research output: Contribution to journal › Article › peer-review

Abstract

Alternative statistical designs cannot fully mitigate the limitations of traditional clinical trials in rare cancers. Creative study designs that integrate early clinical data and correlative outcomes from concomitant translational and laboratory models to evaluate the efficacy of druggable targets can potentially expedite access to novel therapies for these patients.

Original language	English (US)
Pages (from-to)	6069-6071
Number of pages	3
Journal	Clinical Cancer Research
Volume	27
Issue number	22
DOIs	https://doi.org/10.1158/1078-0432.CCR-21-2578
State	Published - Nov 15 2021

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1158/1078-0432.CCR-21-2578

Cite this

@article{6018d9fc534a48bfa86dc3a637512716,

title = "Ruxolitinib in CMML: A case study of innovative trial design in a rare cancer",

abstract = "Alternative statistical designs cannot fully mitigate the limitations of traditional clinical trials in rare cancers. Creative study designs that integrate early clinical data and correlative outcomes from concomitant translational and laboratory models to evaluate the efficacy of druggable targets can potentially expedite access to novel therapies for these patients.",

author = "Aditi Shastri and Adrianzen-Herrera, {Diego A.}",

note = "Publisher Copyright: {\textcopyright} 2021 American Association for Cancer Research.",

year = "2021",

month = nov,

day = "15",

doi = "10.1158/1078-0432.CCR-21-2578",

language = "English (US)",

volume = "27",

pages = "6069--6071",

journal = "Clinical Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research Inc.",

number = "22",

}

TY - JOUR

T1 - Ruxolitinib in CMML

T2 - A case study of innovative trial design in a rare cancer

AU - Shastri, Aditi

AU - Adrianzen-Herrera, Diego A.

PY - 2021/11/15

Y1 - 2021/11/15

N2 - Alternative statistical designs cannot fully mitigate the limitations of traditional clinical trials in rare cancers. Creative study designs that integrate early clinical data and correlative outcomes from concomitant translational and laboratory models to evaluate the efficacy of druggable targets can potentially expedite access to novel therapies for these patients.

AB - Alternative statistical designs cannot fully mitigate the limitations of traditional clinical trials in rare cancers. Creative study designs that integrate early clinical data and correlative outcomes from concomitant translational and laboratory models to evaluate the efficacy of druggable targets can potentially expedite access to novel therapies for these patients.

UR - http://www.scopus.com/inward/record.url?scp=85119927039&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85119927039&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-21-2578

DO - 10.1158/1078-0432.CCR-21-2578

M3 - Article

C2 - 34531297

AN - SCOPUS:85119927039

SN - 1078-0432

VL - 27

SP - 6069

EP - 6071

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 22

ER -

Ruxolitinib in CMML: A case study of innovative trial design in a rare cancer

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this